Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Nvidia ( NASDAQ: NVDA) announced a collaboration with Novo Nordisk ( NVO) ( OTCPK:NONOF) on Wednesday to speed up the Danish ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...